Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
Type:
Application
Filed:
May 12, 2021
Publication date:
June 8, 2023
Applicant:
METABOMED LTD.
Inventors:
Philippe NAKACHE, Omri EREZ, Simone BOTTI, Andreas GOUTOPOULOS, Harry Finch
Abstract: The present invention relates to novel compounds that modulate cellular glucose uptake by affecting various targets, including, but not limited to those related to glycolysis and known transporters/co-transporters of the GLUT family. The compounds according to the invention are useful for treating cancer such as: neuroendocrine neoplasms, gastrointestinal stromal tumors (GIST), renal cell carcinoma, paraganglioma, pheochromocytoma, pituitary adenoma, colorectal cancer, lung cancer, gastric cancer, pancreatic cancer sarcoma, head and neck cancer, melanoma, ovarian cancer and other cancers that rely on high levels of glycolysis for survival and proliferation; as well as in treating of autoimmune diseases, inflammation, infectious diseases, and metabolic diseases.
Type:
Application
Filed:
November 11, 2020
Publication date:
March 16, 2023
Applicant:
METABOMED LTD.
Inventors:
Philippe NAKACHE, Omri EREZ, Simone BOTTI, Andreas GOUTOPOULOS
Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
Type:
Application
Filed:
November 4, 2020
Publication date:
September 29, 2022
Applicant:
METABOMED LTD.
Inventors:
Philippe NAKACHE, Omri Erez, Simone Botti, Andreas Goutopoulos
Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
December 1, 2020
Assignee:
METABOMED LTD.
Inventors:
Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
Type:
Application
Filed:
May 14, 2019
Publication date:
August 29, 2019
Applicant:
METABOMED LTD.
Inventors:
Philippe NAKACHE, Omri EREZ, Simone BOTTI, Andreas GOUTOPOULOS